Molecular imaging may reduce need for melanoma biopsies
Medical Xpress
February 25, 2026
AI-Generated Deep Dive Summary
Molecular imaging technology is paving the way for a non-invasive approach to melanoma detection, potentially reducing the need for biopsies. Dr. Douglas Grossman, a leader in melanoma research at Huntsman Cancer Institute, has helped develop Skin Fluorescent Imaging (SFI), a system that uses fluorescent imaging to analyze moles and lesions without removing skin. This innovative tool evaluates the molecular makeup of suspicious areas, offering a more efficient and less invasive alternative to traditional biopsy methods.
The SFI system, developed by Orlucent, Inc., works by illuminating skin with specific wavelengths of light, allowing it to detect subtle changes in tissue composition that may indicate melanoma. By providing real-time feedback on the molecular characteristics of moles and lesions, SFI helps healthcare providers make more informed decisions during screenings. This technology is particularly promising for early-stage melanoma detection, as it can identify potentially cancerous areas with high accuracy while minimizing unnecessary procedures.
The significance of this advancement lies in its potential to revolutionize melanoma care. By reducing the number of biopsies required, SFI not only enhances patient comfort but also streamlines clinical workflows. This technology could lead to more efficient screenings, particularly in settings where resources are limited or where large populations need regular monitoring. For patients, this means less anxiety and risk associated with biopsy procedures, while for providers, it offers a powerful new tool in the fight against melanoma.
The broader impact of SFI extends beyond individual patient care. By improving diagnostic accuracy and reducing overtreatment, this technology
Verticals
healthmedical
Originally published on Medical Xpress on 2/25/2026